Conditions: Nausea Vomiting
Keywords: autologous myeloma transplant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: no

Brief summary:
The purpose of this study is to help answer the following research question:

* Whether administration of an aprepitant containing regimen, an olanzapine containing regimen or regimen containing both will prevent nausea and vomiting better for patients undergoing an autologous stem cell transplant with melphalan chemotherapy. Both of these medications are approved by the United States Food and Drug Administration (FDA) for nausea and vomiting.
* Participants will be randomly assigned to one of the 3 treatment groups:

  * Arm A: aprepitant containing anti-emetic therapy
  * Arm B: olanzapine containing anti-emetic therapy
  * Arm C: Aprepitant plus olanzapine containing anti-emetic therapy

Detailed description:
This is a multi-center, randomized, non-inferiority phase 3 study conducted to determine an appropriate anti-emetic regimen for patients receiving melphalan for an autologous stem cell transplant (SCT). Candidates for this trial will include patients aged 18-80 years with hematologic malignancies receiving high dose melphalan as part of a conditioning regimen for an autologous stem cell transplant. Patients will be enrolled in 3 arms. Patients in Arm A will receive an aprepitant containing anti-emetic regimen. Patients in Arm B will receive an olanzapine containing anti-emetic regimen. Patients in Arm C will receive an aprepitant plus olanzapine containing anti-emetic regimen. Patients must be able to tolerate oral medications.

Patients will be carefully monitored for rates of emesis, nausea, and mucositis. Any adverse events will be recorded. Impact on quality of life will also be assessed. A total of 184 patients will be accrued to each arm. It is anticipated that the accrual period will last approximately 2-3 years. The primary endpoint of this study is a complete response, defined as no emesis and no rescue therapy within 120 hours of melphalan administration.

Arms:
arm 1: aprepitant plus standard anti-emetic regimen arm 2: olanzapine plus standard anti-emetic regimen arm 3: aprepitant and olanzapine plus standard anti-emetic regimen

Interventions: intervention 1: o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1 intervention 2: Olanzapine10 mg orally daily on Days -1,0,+1 and +2 intervention 3: Aprepitant plus Olanzapine
Intervention descriptions: intervention 1: Add aprepitant to anti-emetic regimen intervention 2: add olanzapine to anti-emetic regimen intervention 3: add aprepitant and olanzapine to anti-emetic regimen

Protocol document:
Prot_SAP_ICF_003.pdf: 
RUSH UNIVERSITY MEDICAL CENTER IRB PROTOCOL 
ORA: 14102001-IRB01 Date IRB Approved: 10/1/2018 Amendment Date: 4/22/2019  
RB#: 14102001 
NCT#: NCT02939287 
Aprepitant- and olanzapine- containing regimens for prevention of acute and delayed nausea and 
vomiting associated with high dose melphalan and BEAM in autologous stem cell transplant patients 
PROTOCOL FACE PAGE 
 
Clinician 
Institution 
Department 
Principal Investigator(s): 
Amanda Seddon, PharmD 
RUMC 
Pharmacy 
Co-Principal Investigators: 
Sunita Nathan, MD 
Celalettin Ustun, MD 
Lisa Wendt, PharmD 
Danielle Murphy, PharmD 
Brian Seyboth, PharmD 
Rebecca Myers, PharmD 
Aaron Krapfl, PharmD 
Justin Fisher, PharmD 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
Bone Marrow Transplant 
Bone Marrow Transplant 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Consenting 
Professional(s): 
Danielle Murphy, PharmD 
Rebecca Myers, PharmD 
Aaron Krapfl, PharmD 
Amanda Seddon, PharmD 
Justin Fisher, PharmD 
Brian Seyboth, PharmD 
Sunita Nathan, MD 
Ashely Echeverria, PA 
Mallory Weber, PA 
Jackie Baptista, NP 
Emilee Moeke, RN 
Karla Cavazos, RN 
Celalettin Ustun, MD 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
RUMC 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Pharmacy 
Bone Marrow Transplant 
Bone Marrow Transplant 
Bone Marrow Transplant 
Bone Marrow Transplant 
Bone Marrow Transplant 
Bone Marrow Transplant 
Bone Marrow Transplant 
 
Please Note: A Consenting Professional must have completed the mandatory Human Subjects Education 
and Certification Program 
 
 


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Aprepitant- and olanzapine- containing regimens for prevention of acute and delayed nausea and 
vomiting associated with high dose melphalan and BEAM in autologous stem cell transplant patients
PROTOCOL FACE PAGE
Clinician
Institution
Department
Principal Investigator(s):
Lisa DiGrazia, PharmD
Kathryn Schultz, PharmD
RUMC
RUMC
Pharmacy
Pharmacy
Co-Principal Investigators:
Sunita Nathan, MD
Celalettin Ustun, MD
Amanda Seddon, PharmD
Eris Tollkuci, PharmD
Brian Seyboth, PharmD
Rebecca Myers, PharmD
Zach Click, PharmD
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
Bone Marrow Transplant
Bone Marrow Transplant
Pharmacy
Pharmacy
Pharmacy
Pharmacy
Pharmacy
Consenting 
Professional(s):
Lisa DiGrazia, PharmD
Rebecca Myers, PharmD
Sunita Nathan, MD
Kathryn Schultz, PharmD
Amanda Seddon, PharmD
Eris Tollkuci, PharmD
Zach Click, PharmD
Ashely Echeverria, PA
Mallory Weber, PA
Jackie Baptista, NP
Laura Zider, NP
Colleen Bruen, RN
Emilee Moeke, RN
Karla Cavazos, RN
Brian Seyboth, PharmD
Celalettin Ustun, MD
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
RUMC
Pharmacy
Pharmacy
Bone Marrow Transplant
Pharmacy
Pharmacy
Pharmacy
Pharmacy
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplant
Pharmacy
Bone Marrow Transplant
Please Note: A Consenting Professional must have completed the mandatory Human Subjects Education 
and Certification Program
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Table of Contents
1.
Protocol Summary
2.
Objectives
3.
Background and Rationale
4.
Therapeutic Agents
5.
Criteria for Subject Eligibility
6.
Recruitment Plan
7.
Pretreatment Evaluation
8.
Treatment/Intervention Plan
9.
Evaluation During Treatment/Intervention
10. Toxicities/Side Effects
11. Criteria for Therapeutic Response/Outcome Assessment
12. Criteria for Removal from Study
13. Biostatistics
14. Research Participant Registration and Randomization Procedures
15. Data Management Issues
16. Protection of Human Subjects
17. Informed Consent Procedures
18. References
19. Appendix
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Abbreviations
5-HT3
Serotonin
ADAMHA
Alcohol, Drug Abuse, and Mental Health Administration
ANC
Absolute Neutrophil Count
ASCO
American Society of Clinical Oncology
ASCT
Autologous Stem Cell Transplant
BEAM
Carmustine (BiCNU); Etoposide; Cyarabine (Ara-C);Melphalan
CINV
Chemotherapy Inducted Nausea and Vomiting
CNS
Central nervous system
CR
Complete response
EKG
Electrocardiogram
ESMO
European Society of Medical Oncology (ESMO)
FLIE
Functional Living Index-Emesis
HIV
Human immunodeficiency virus
IRB
Institutional Review Board
MASCC
Multinational Association of Supportive Care in Cancer
NCCN
National Comprehensive Cancer Network
NIH
National Institutes of Health
QTc
Corrected QT interval
RUMC
Rush University Medical Center
SAE
Serious Adverse Events
SCT
Stem Cell Transplant
VAS
Visual Analog Scale
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
1.
PROTOCOL SUMMARY
This is a multi-center, randomized, non-inferiority phase 3 study conducted to determine an 
appropriate anti-emetic regimen for patients receiving melphalan for an autologous stem cell 
transplant (SCT). Candidates for this trial will include patients aged 18-80 years with hematologic 
malignancies receiving high dose melphalan as part of a conditioning regimen for an autologous stem 
cell transplant. Patients will be enrolled in 3 arms. Patients in Arm A will receive an aprepitant 
containing anti-emetic regimen. Patients in Arm B will receive an olanzapine containing anti-emetic 
regimen. Patients in Arm C will receive an aprepitant plus olanzapine containing anti-emetic regimen. 
Patients must be able to tolerate oral medications.
Patients will be carefully monitored for rates of emesis, nausea, and mucositis. Any adverse events 
will be recorded. Impact on quality of life will also be assessed. A total of 184 patients will be accrued 
to each arm. It is anticipated that the accrual period will last approximately 2-3 years. The primary 
endpoint of this study is a complete response, defined as no emesis and no rescue therapy within 
120 hours of melphalan administration.
2.
OBJECTIVES
The primary aim of this study is to obtain an overall complete response (CR), defined as no emesis 
and no rescue therapy within 120 hours of melphalan administration. The time interval of 120 hours 
was chosen because it can be assumed that additional cofactors (e.g., mucositis and antibiotic use) 
influence rates of nausea and vomiting after this point in time. 
Secondary objectives include:

Acute CR, defined as no emesis or rescue therapy in 0 to 24 hours

Delayed CR, defined as no emesis or rescue therapy in 25 to 120 hours

Very delayed CR, defined as no emesis in 121 to 168 hours

Rates of emesis

Nausea (Any) 

Significant nausea

Mucositis (Any) 

Significant mucositis

Impact on quality of life

Time to neutrophil and/or platelet engraftment (days)
At study completion an estimate of the efficacy of aprepitant or olanzapine containing anti-emetic 
regimens in preventing nausea and vomiting after high dose melphalan in stem cell transplant 
patients will be possible.
3.
BACKGROUND AND RATIONALE
High dose melphalan, by itself or in combination with other chemotherapy, is a very common 
alkylating agent used in conditioning regimens for autologous stem cell transplant. Acute toxicities of 
high dose melphalan include myelosuppression, mucositis, hepatotoxicity, and nausea and vomiting. 
Chemotherapy inducted nausea and vomiting (CINV) has been patient reported as one of the most 
feared adverse effects of patients receiving chemotherapy (Bloechl-Daum, et al 2006). Without 
appropriate supportive care, patients could experience significant acute and delayed CINV with 
melphalan. 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
When first introduced serotonin (5-HT3) antagonists, alone or combined with dexamethasone, 
improved rates of nausea and emesis in stem cell transplant patients (Ballen et al, 2001; Einhorn et 
al, 2011). The addition of aprepitant, a neurokinin-1 antagonist, to 5HT3 antagonists and 
dexamethasone in SCT patients receiving high dose melphalan has been shown to be beneficial in 
preventing CINV (Jordan et al, 2011; Pieliechowski et al, 2011; Stiff et al, 2013; Schmitt et al, 2014; 
Bechtel et al, 2014).
Most commonly used guidelines for anti-emetic therapy for CINV include ASCO, MASCC/ESMO, and 
NCCN.1-3 ASCO guidelines recommend to consider aprepitant in combination with a 5-HT3 antagonist 
and dexamethasone for high dose chemotherapy with stem cell or bone marrow transplant.1 
MASCC/ESMO guidelines recommend aprepitant in combination with 5-HT3 antagonist and 
dexamethasone for patients who are at high or moderate risk for delayed CINV.2 NCCN classifies 
melphalan as a moderate emetic risk agent, resulting in 30-90% of patients experiencing CINV 
without supportive anti-emetics.3 Historically, a 5-HT3 antagonist and dexamethasone ± aprepitant 
was the only recommended option for moderate emetic risk chemotherapy.3 Recently, the NCCN 
added an olanzapine regimen to the anti-emetic guidelines for moderate-high emetic risk regimens 
and an olanzapine + aprepitant regimen for high emetic risk regimens (Table 1).3 Differences in 
guideline recommendations are due to lack of evidence for appropriate anti-emetic regimen in the 
SCT patient population.
Table 1: Summary of recommendations for anti-emetic therapy in patients receiving melphalan
ASCO
MASCC/ESMO
NCCN
NCCN
Updated
2011
2013
2014
2018
Criteria
High dose 
chemotherapy with 
stem cell rescue
High to moderate risk 
delayed CINV
Moderate risk 
agents (Melphalan)
Moderate risk 
agents (Melphalan)
High risk 
(Carmustine)
Recommenda
tion
Aprepitant +
5-HT3 antagonist +
dexamethasone
Aprepitant +
5-HT3 antagonist +
dexamethasone
5-HT3 antagonist +
Dexamethasone ±
Aprepitant
OR
Olanzapine +
5-HT3 antagonist +
Dexamethasone
Olanzapine
+
Aprepitant +
5-HT3 antagonist
+
Dexamethasone
Olanzapine is an atypical antipsychotic that blocks multiple neurotransmitters in the central nervous 
system (Navari et al, 2014). The exact mechanism of olanzapine reducing CINV is unknown; 
however, it blocks dopamine and serotonin neurotransmitters, possibly contributing to its anti-emetic 
effect (Navari et al, 2014).
Olanzapine has been studied in phase I-III trials for the prevention of CINV in patients receiving highly 
emetogenic chemotherapy for solid tumors (Navari et al, 2014). In a phase III trial by Navari et al, 
chemotherapy naïve patients who received cisplatin or cyclophosphamide and doxorubicin for solid 
tumors were randomized to either olanzapine or aprepitant in combination with palonosetron and 
dexamethasone (Table 2). Olanzapine, palonosetron, and dexamethasone were comparable to 
aprepitant, palonosetron, and dexamethasone in the control of chemotherapy induced emesis (Table 
2). Nausea was significantly better controlled with the olanzapine containing regimen (Table 2). This 
study led to the addition of olanzapine in the NCCN anti-emesis guidelines for the prevention of CINV 
in patients receiving highly or moderately emetogenic regimens. 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Table 2: Results of olanzapine or aprepitant in combination with palonosetron and dexamethasone in 
patients receiving highly emetic chemotherapy. (Navari et al, 2011).
Olanzapine Arm
N = 121
Aprepitant Arm
N = 120
Treatment
Day 1: Olanzapine 10 mg, 
palonosetron 0.25 mg, 
dexamethasone 20 mg
Day 2-4: Olanzapine 10 mg 
QD
Day 1: Aprepitant 125 mg, 
palonosetron 0.25 mg, and 
dexamethasone 12 mg
Day 2-3: Aprepitant 80 mg QD 
and dexamethasone 4 mg BID
Acute CR (24 hours)
97%
87%
Delayed CR (2-5 days)
77%
73%
Overall CR (0-120 hours)
77%
73%
Without acute nausea
87%
87%
Without delayed nausea
69%
38%
Without overall nausea
69%
38%
*CR was no emesis or no rescue medications
Olanzapine is now an acceptable option for patients receiving highly or moderately emetogenic 
chemotherapy (NCCN). Olanzapine is not a cytochrome P450 inhibitor and would have minimal drug 
interactions (Bymaster et al, 1996). In addition, olanzapine may reduce opioid requirements in cancer 
patients with uncontrolled pain, cognitive impairment, or anxiety (Khojainova et al, 2002; Navari et al, 
2014). Side effects of olanzapine are listed in Section 10.4. Aprepitant, due to high cost, is often not 
covered under patient insurance plans, and with autologous SCTs moving to the outpatient setting, 
olanzapine would be an attractive option. In conclusion, olanzapine may be a potential alternative for 
use in the SCT patient population. To our knowledge, this is the first study comparing aprepitant to 
olanzapine in patients receiving high dose melphalan or BEAM in preparation for an autologous SCT. 
4.
THERAPEUTIC AGENTS
4.1 Melphalan
Supplied as: 50 mg vial
Reconstitution directions: The sterile diluents contains sodium citrate 0.2 g, propylene glycol 6 ml, 
ethanol (96%) 0.52 ml, and water for injection for a total of 10 ml
Storage and stability: 

Store vials at room temperature

Protect from light

Do not refrigerate the reconstituted product

Reconstituted solutions must be further diluted immediately, discard unused portion

Drug administration must be completed within 60 minutes of initial reconstitution.
Preparation: Reconstitute by rapidly injecting 10 ml of the supplied diluents into the vial to yield a final 
concentration of 5 mg/ml. Shake vigorously until the solution is clear. Immediately dilute the dose to 
be administered in 0.9% Sodium Chloride, USP, to a concentration no greater than 0.45 mg/ml. 
Refrigerated storage of the reconstituted product results in precipitation
Clinical considerations: Hydration pre and post melphalan per RUMC guidelines
Toxicities: See Section 10.0
4.2 Aprepitant
Supplied as: 40 mg, 80 mg, and 125 mg capsules
Storage and stability: Store at room temperature
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Clinical considerations: May be taken with or without food. Aprepitant is a substrate of CYP3A4 and 
coadministration with drugs that inhibit or induce CYP3A4 may result in increased or reduced plasma 
concentrations of aprepitant. Aprepitant is an inducer of CYP2C9 and coadministration with drugs that 
are metabolized by CYP2C9 may result in lower plasma concentrations of these drugs.
Toxicities: See Section 10.0
4.3 Olanzapine
Supplied as: 2.5, 5, 7.5, 10, 15, and 20 mg tablets; 5, 10, 15, 20 mg orally disintegrating tablets
Storage and stability: Store at room temperature. Protect tablets from light and moisture.
Clinical considerations: May schedule in the evening with or without food
Toxicities: See Section 10.0
4.4 Ondansetron
Supplied as: 4, 8 mg tablets; 4, 8 mg orally disintegrating tablets (ODT); 40 mg/ml oral solution; 2 
mg/ml injection; 20 mL multidose vials
Storage and stability: Store at room temperature. Protect oral solution from light.
Clinical considerations: May take with or without food. Ondansetron ODT place on top of tongue 
where it will dissolve in seconds, than swallow saliva. Administration with liquid is not necessary. 
Toxicities: See Section 10.0
4.5 Dexamethasone
Supplied as: 0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; 0.5 mg/5mL and 1 mg/mL solutions for oral 
administration; 4mg/mL and 10 mg/mL injection for intravenous or intramuscular use
Storage and stability: Store tablets and solution at room temperature. Protect from moisture and 
dispense in a well closed light resistant container. Discard oral opened bottle after 90 days. 
Intravenous injection should be stored at room temperature and protected from light.
Clinical considerations: May take with or without food. Recommend with food to prevent upset 
stomach.
Toxicities: See Section 10.0
5.
CRITERIA FOR SUBJECT ELIGIBILITY
5.1 Subject Inclusion Criteria:

Age
o
18-80 years

Autologous transplantation containing high dose melphalan as part of the conditioning 
regimen
o
Single or two day melphalan
o
BEAM (carmustine, etoposide, cytarabine, melphalan)

Able to tolerate oral medications
5.2 Subject Exclusion Criteria:

Nausea and vomiting within 12 hours before planned high dose conditioning chemotherapy

Any antiemetic treatment within 24 hours before planned high dose conditioning 
chemotherapy

Pregnancy

Baseline QTc > 500ms

History of seizures
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001

History of central nervous system (CNS) disease

Human immunodeficiency virus (HIV)
6.
RECRUITMENT PLAN
Patients will be considered for this protocol and recruited as appropriate according to their selected 
conditioning regimen for their autologous SCT. Patients who fulfill the eligibility criteria as listed in 
Section 5 will be recruited by a SCT attending prior to admission. Informed consent will be obtained 
by one of the participating investigators authorized to obtain consent. 
After consent is obtained, confirmation of patient eligibility will be done by the oncology research 
pharmacist or SCT pharmacist. Confirmation of patient eligibility will be performed the day of 
admission followed by randomization. 
This protocol will take due notice of NIH/ADAMHA policies concerning inclusion of women and 
minorities in clinical research populations. We expect that the study population will be fully 
representative of the range of patients referred for transplant without exclusion as to age, gender, or 
ethnic background within the limits of transplant eligibility. Pregnant women are excluded from 
participation in this study.
Rush University Medical Center will serve as the primary site for Phase 1 of this study.  After a 
sufficient number of patients are successfully enrolled or 6 months passes and no research plan 
amendments are to be considered, then other sites will be enrolled to continue the same study for 
Phase 2. 
7.
PRETREATMENT EVALUATION
The following tests must be performed prior to starting pre-transplant conditioning regimen:

EKG
8.
TREATMENT/INTERVENTION PLAN
The selection of conditioning regimen most appropriate for the patient based on their disease status, 
age, extent of prior therapy, organ function and presence of significant co-morbidities is done by the 
treating SCT physician. All patients to be included in this study will be treated with high dose 
melphalan or BEAM. All patients will be admitted to the SCT Unit. The treating SCT physician will 
select the conditioning regimen most appropriate for the patient based on their disease status, age, 
extent of prior therapy, organ function and presence of significant co-morbidities. All patients will be 
treated with high dose melphalan or BEAM. 
Patients will be randomized to the following treatment arms:

Arm A: Aprepitant containing  anti-emetic therapy

Arm B: Olanzapine containing anti-emetic therapy

Arm C: Aprepitant plus olanzapine containing anti-emetic therapy
Schedule of anti-emetic therapy is based on conditioning chemotherapy regimen and outlined in 
Section 8.1. 
Post treatment anti-emetic therapy is outlined in Section 8.3.
8.1 Treatment Schedule
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001

Conditioning regimen: One day melphalan
ARM A: Patients receiving one day melphalan and randomized to aprepitant will receive:
Day
-1
0
ASCT
+1
+2
Melphalan
X
Aprepitant
125 mg
80 mg
80 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
o
Melphalan: 140-200 mg/m2/day IV given on Day -1
o
ASCT: stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally 
on Days 0 and +1 
o
Ondansetron: 16 mg orally daily on Days -1,0,+1 and +2
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on day -1 and 8 mg 
orally on days 0, +1 and +2. Dose may be given as 4 mg orally twice daily on days 0 
to +2. The dose of dexamethasone was reduced when co-administered with 
aprepitant according to recommended highly emetogenic regimen in the Emend® 
package insert.
ARM B: Patients receiving one day melphalan and randomized to olanzapine will receive:
Day
-1
0
ASCT
+1
+2
Melphalan
X
Olanzapine
10 mg
10 mg
10 mg
10 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
Dexamethasone
20 mg
8 mg
8 mg
8 mg
o
Melphalan: 140-200 mg/m2/day IV given on Day -1 
o
ASCT: stem cell rescue on Day 0
o
Olanzapine: 10 mg orally daily on Days -1,0,+1 and +2
o
Ondansetron: 16 mg orally daily on Days -1,0,+1 and +2
o
Dexamethasone: 20 mg orally 30 minutes prior to chemotherapy on Day -1 and 8 mg 
orally on days 0 to +2. Dose may be given as 4 mg orally twice daily on Days 0 to +2.  
Arm C: Patients receiving one day melphalan and randomized to aprepitant + olanzapine will 
receive:
Day
-1
0
ASCT
+1
+2
Melphalan
X
Aprepitant
125 mg
80 mg
80 mg
Olanzapine
10 mg
10 mg
10 mg
10 mg
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Ondansetron
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
o
Melphalan: 140-200 mg/m2/day IV given on Day -1 
o
ASCT: stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally 
on Days 0 and +1 
o
Olanzapine: 10 mg orally daily on Days -1,0,+1 and +2
o
Ondansetron: 16 mg orally daily on Days -1,0,+1 and +2
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on Day -1 and 8 mg 
orally on days 0 to +2. Dose may be given as 4 mg orally twice daily on Days 0 to +2.  

Conditioning regimen: Two day melphalan
ARM A: Patients receiving two day melphalan and randomized to aprepitant will receive:
Day
-2
-1
0
ASCT
+1
+2
Melphalan
X
X
Aprepitant
125 mg
80 mg
80 mg
80 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
8 mg
o
Melphalan: 100 mg/m2/day IV given on Days -2 and -1
o
ASCT: Stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -2 and 80 mg orally 
on Days -1, 0, and +1 
o
Ondansetron: 16 mg orally daily on Days -2, -1, 0, +1, and +2
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on day -2 and 8 mg 
orally on Days -1, 0, +1 and +2. Dose may be given as 4 mg orally twice daily on 
Days -1, 0, +1 and +2. The dose of dexamethasone was reduced when 
coadministered with aprepitant according to recommended highly emetogenic 
regimen in the Emend® package insert.
ARM B: Patients receiving two day melphalan and randomized to olanzapine will receive:
Day
-2
-1
0
ASCT
+1
+2
Melphalan
X
X
Olanzapine
10 mg
10 mg
10 mg
10 mg
10 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
20 mg
8 mg
8 mg
8 mg
8 mg
o
Melphalan: 100 mg/m2/day IV given on Days -2 and -1
o
ASCT: Stem cell rescue on Day 0
o
Olanzapine: 10 mg orally daily on Days -2, -1, 0, +1, and +2
o
Ondansetron: 16 mg orally on daily on Days -2, -1, 0, +1, and +2
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
o
Dexamethasone: 20 mg orally 30 minutes prior to chemotherapy on day -2 and 8 mg 
orally on Days -1, 0, +1 and +2. Dose may be given as 4 mg orally twice daily on 
Days -1, 0, +1 and +2.  
Arm C: Patients receiving two day melphalan and randomized to aprepitant + olanzapine will 
receive:
Day
-2
-1
0
ASCT
+1
+2
Melphalan
X
X
Aprepitant
125 mg
80 mg
80 mg
80 mg
Olanzapine
10 mg
10 mg
10 mg
10 mg
10 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
8 mg
o
Melphalan: 100 mg/m2/day IV given on Days -2 and -1
o
ASCT: Stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -2 and 80 mg orally 
on Days -1, 0, and +1 
o
Olanzapine: 10 mg orally daily on Days -2, -1, 0, +1, and +2
o
Ondansetron: 16 mg orally on daily on Days -2, -1, 0, +1, and +2
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on day -2 and 8 mg 
orally on Days -1, 0, +1 and +2. Dose may be given as 4 mg orally twice daily on 
Days -1, 0, +1 and +2.  

Conditioning regimen: BEAM
ARM A: Patients receiving BEAM and randomized to aprepitant will receive:
Day
-6
-5 to -2
-1
0
ASCT
+1
+2
Carmustine
X
Etoposide
X
Cytarabine
X
Melphalan
X
Aprepitant
125 mg
80 mg
80 mg
80 mg
80 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
8 mg
8 mg
o
Carmustine: 300 mg/m2/day IV given on Day -6
o
Etoposide: 200 mg/m2 IV twice daily on Days -5 to -2
o
Cytarabine: 200 mg/m2 IV twice daily on Days -5 to -2 (Give after etoposide)
o
Melphalan: 140 mg/m2/day IV given on Day -1 
o
ASCT: Stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -6 and 80 mg orally 
on Days -5, - 4, -3, -2, -1, 0, and +1
o
Ondansetron: 16 mg orally daily on Days -6, -5, - 4, -3, -2, -1, 0, +1, and +2
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on Day -6 and 8 mg 
orally daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2. Dose may be given as 4 mg 
orally twice daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2. The dose of 
dexamethasone was reduced when co-administered with aprepitant according to 
recommended highly emetogenic regimen in the Emend® package insert.
ARM B: Patients receiving BEAM and randomized to the olanzapine will receive:
Day
-6
-5 to -2
-1
0
ASCT
+1
+2
Carmustine
X
Etoposide
X
Cytarabine
X
Melphalan
X
Olanzapine
10 mg
10 mg
10 mg
10 mg
10 mg
10 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
20 mg
8 mg
8 mg
8 mg
8 mg
8 mg
o
Carmustine: 300 mg/m2/day IV given on Day -6
o
Etoposide: 200 mg/m2 IV twice daily on Days -5 to -2
o
Cytarabine: 200 mg/m2 IV twice daily on Days -5 to -2 (Give after etoposide)
o
Melphalan: 140 mg/m2/day IV given on Day -1
o
ASCT: Stem cell rescue on Day 0
o
Olanzapine: 10 mg orally daily on Days -6, -5, - 4, -3, -2, -1, 0, +1, and +2
o
Ondansetron: 16 mg orally daily on Days -6, -5, - 4, -3, -2, -1, 0, +1, and +2
o
Dexamethasone: 20 mg orally 30 minutes prior to chemotherapy on Day -6 and 8 mg 
orally daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2. Dose may be given as 4 mg 
orally twice daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2.
ARM C: Patients receiving BEAM and randomized to the aprepitant + olanzapine will receive:
Day
-6
-5 to -2
-1
0
ASCT
+1
+2
Carmustine
X
Etoposide
X
Cytarabine
X
Melphalan
X
Aprepitant
125 mg
80 mg
80 mg
80 mg
80 mg
Olanzapine
10 mg
10 mg
10 mg
10 mg
10 mg
10 mg
Ondansetron
16 mg
16 mg
16 mg
16 mg
16 mg
16 mg
Dexamethasone
12 mg
8 mg
8 mg
8 mg
8 mg
8 mg
o
Carmustine: 300 mg/m2/day IV given on Day -6
o
Etoposide: 200 mg/m2 IV twice daily on Days -5 to -2
o
Cytarabine: 200 mg/m2 IV twice daily on Days -5 to -2 (Give after etoposide)
o
Melphalan: 140 mg/m2/day IV given on Day -1
o
ASCT: Stem cell rescue on Day 0
o
Aprepitant: 125 mg orally one hour prior to chemotherapy on Day -6 and 80 mg orally 
on Days -5, - 4, -3, -2, -1, 0, and +1
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
o
Olanzapine: 10 mg orally daily on Days -6, -5, - 4, -3, -2, -1, 0, +1, and +2
o
Ondansetron: 16 mg orally daily on Days -6, -5, - 4, -3, -2, -1, 0, +1, and +2
o
Dexamethasone: 12 mg orally 30 minutes prior to chemotherapy on Day -6 and 8 mg 
orally daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2. Dose may be given as 4 mg 
orally twice daily on Days -5, - 4, -3, -2, -1, 0, +1, and +2.
8.2 Rescue Anti-emetics
Rescue medication for breakthrough CINV is left up to the discretion of the treating physician. For 
additional information on rescue therapy for CINV see Section 11.3.
8.3 Anti-emetic Therapy Post Treatment/Intervention
Anti-emetic medication will be administered post treatment/intervention plan according to institutional 
protocols. 
9.
EVALUATION DURING TREATMENT/INTERVENTION
In the pre-study period, all pertinent demographics (age and gender) and medical data (site, 
underlying malignancy, ECOG rating, and conditioning chemotherapy) will be recorded. 
Subjects will be provided the standard of care according to each institution’s guidelines. Subjects will 
be evaluated for primary and secondary outcomes using a diary that includes the following tools:

Record episodes of vomiting and/or retching and rescue therapy completed daily for 7 days

Visual analog scale (VAS) on a 10 mm scale to record nausea/mucositis and its severity (See 
Appendix 19.1) completed daily for 7 days
o
VAS < 1 no nausea/mucositis
o
VAS 1-3 mild nausea/mucositis
o
VAS 4-7 moderate nausea/mucositis
o
VAS 8-10 severe nausea/mucositis

Functional Living Index-Emesis (FLIE) questionnaire assessed quality of life (See Appendix 
19.2). Baseline was obtained on Day -1 and repeated on the morning of Day +5.
Subjects will be asked to record a daily dairy for episodes of vomiting/retching (number and time) and 
rescue therapy. Daily episodes of nausea/mucositis using a visual analogue scale from 0 to 10, with 0 
indicating no nausea/mucositis and 10 indicating maximal nausea/mucositis. Each subject will receive 
7 forms to complete as the diary will be recorded over a period of 7 days. Time 0 is end of melphalan 
infusion. An attending, advanced practice professional, pharmacist or pharmacy student contacted 
each subject every 24 hours to remind the subject to complete the forms. If a pharmacist or pharmacy 
student is unavailable (e.g. weekend coverage), the attending physician or advanced practice 
professional.

Form 1: 0-24 hours

Form 2: 25-48 hours

Form 3: 49-72 hours

Form 4: 73-96 hours

Form 5: 97-120 hours

Form 6: 121-144 hours

Form 7: 145-168 hours
In addition, attending physician will document in daily progress notes complaints of nausea and or 
emesis. 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
10. TOXICITIES/SIDE EFFECTS
10.1
Toxicity Grading
Toxicities will be graded on a sale of 0 to 4 as described by the NCI-Common Terminology for 
Adverse Events (CTCAE), version 4.0. Adverse events were recorded and graded by the 
principal investigator as mild (temporary event well tolerated by the patient), moderate (event 
resulting in discomfort for patient and impairing normal daily activity), or severe (event resulting in 
substantial impairment of normal daily activity). 
10.2
Melphalan
The major toxicity of melphalan toxicity is myelosuppression and is treated by donor stem cell 
infusion and supportive care. Most patients will develop moderate to severe mucositis of the oral 
and GI tracts which is prevented with cryotherapy and managed with supportive care. Acute and 
delayed nausea and vomiting will be experienced after high dose melphalan and can be 
significantly diminished with anti-emetics. Most patients develop diarrhea and this is treated 
symptomatically. High doses of melphalan may contribute to damage of vital organs such as the 
liver, kidney, or lung. Late effects include sterility and secondary malignancies.
10.3
Aprepitant
Side effects experienced in conjunction with highly and moderately emetogenic chemotherapy 
included alopecia, anorexia, asthenia, fatigue, constipation, diarrhea, hiccups, and nausea. Rare 
but serious side effects include Stevens-Johnson syndrome/toxic epidermal necrolysis and 
hypersensitivity reactions.
10.4
Olanzapine
Side effects include dizziness, postural hypotension, constipation, somnolence, and tremor. Other 
likely side effects include hyperglycemia, hyperlipidemia, weight gain, and increased appetite. 
Rare but serious side effects include seizures, tardive dyskinesia neuroleptic malignant 
syndrome, and neutropenia. Boxed warnings for increased risk of death and suicide are reported 
for patients who are elderly with dementia-related psychosis who are prescribed olanzapine as an 
anti-psychotic. 
10.5
Ondansetron
Side effects include headache, malaise, fatigue, constipation, diarrhea, and dizziness. Rare but 
serious side effects reported include hypersensitivity reactions, and QT interval prolongation.
10.6
Dexamethasone
Side effects include fluid and electrolyte disturbances, hyperglycemia, cardiac abnormalities, 
abdominal distention, elevation in serum liver enzyme levels, hepatomegaly, and increased 
appetite. Dermatologic side effects include acne, allergic dermatitis, dry scaly skin, ecchymosis 
and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, thin fragile 
skin, thinning scalp hair, and urticaria. Long term use can lead to musculoskeletal side effects 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
including loss of muscle mass, osteoporosis, pathologic fracture of long bones, steroid myopathy, 
and tendon rupture. Neurologic side effects reported include convulsions, depression, emotional 
instability, euphoria, headache, insomnia, mood swings, neuritis, neuropathy, paresthesia, 
personality changes, psychic disorders, and vertigo. Rare ophthalmic side effects include 
exophthalmos, glaucoma, increased intraocular pressures, and posterior subcapsular cataracts. 
Other likely side effects reported include abnormal fat deposits, decreased resistance to infection, 
hiccups, malaise, and mood face.
The definitions and reporting of serious adverse events (SAEs) is defined in Section 16.2.
11. CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT 
Clinical endpoints: The primary aim of this study is to obtain an overall complete response (CR), 
defined as no emesis and no rescue therapy within 120 hours of melphalan administration. Acute CR, 
delayed CR, rates of emesis, nausea, significant nausea, rates of mucositis, adverse events, and 
impact on quality of life will be monitored as secondary endpoints.
11.1
Complete response, acute and delayed complete response
Patients will be monitored by the SCT team including attending physicians, advanced practice 
professionals, pharmacists, and/or nurses. 
An overall complete response is defined as no emesis and no rescue therapy within 120 hours 
of melphalan administration. The time interval of 120 hours was chosen because it can be 
assumed that additional cofactors (e.g., mucositis and antibiotic use) influence rates of nausea 
and vomiting after this point in time.
Acute complete response is defined as no emesis or rescue therapy in 0 to 24 hours. Delayed 
complete response is defined as no emesis or rescue therapy in 25 to 120 hours. Very delayed 
complete response is defined as no emesis in 121 to 168 hours.
Rates of emesis and use of rescue therapy will be collected as described in Sections 11.2 and 
11.3.
11.2
Rates of emesis, nausea, significant nausea, and rates of mucositis
Rates of emesis, nausea, and mucositis will be documented and collected daily using the subject 
diary (See Appendix 19.1). 
A Visual analog scale (VAS) on a 10 mm scale will be used to record nausea/mucositis and its 
severity (See Appendix 19.1). This will be assessed and completed daily for 7 days using the 
following severity scale:
o
VAS < 1 no nausea/mucositis
o
VAS 1-3 mild nausea/mucositis
o
VAS 4-7 moderate nausea/mucositis
o
VAS 8-10 severe nausea/mucositis
11.3
Rescue therapy
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Rescue therapy will be documented daily in the subject diary. In addition, rescue therapy will be 
collected by viewing the Medication Administration Record in the electronic patient chart. Rescue 
medications for CINV include the following:

Any additional doses for CINV including:
o
Aprepitant
o
Dexamethasone
o
Olanzapine
o
Ondansetron

Any doses for CINV including:
o
Any other 5HT3 antagonist
o
Dronabinol
o
Haloperidol
o
Metoclopramide
o
Nabilone
o
Prochlorperazine
o
Promethazine
o
Scopolamine
The use of proton pump inhibitors and hydrogen receptor blockers are allowed and may be used 
at the discretion of the treating physician. In addition, benzodiazepines were allowed in this 
patient population as they are used for various indications, including anxiety and insomnia. 
11.4
Quality of life
Quality of life will be assessed by the FLIE Questionnaire (See Appendix 19.2). This will be 
assessed and completed by subjects at baseline, on Day -1 (if baseline is different than day -1) 
and repeated the morning of Day +5. 
The FLIE is a validated nausea and vomiting specific patient-reported outcome instrument 
comprising of two domains (Nausea and Vomiting) with nine identical items in each domain. The 
first item in each domain asks the patient to rate how much nausea (vomiting) he/she has 
experiences over the past five days. The remaining eight items assess the impact of nausea 
(vomiting) on the following aspects of patient’s daily life: ability to enjoy meals/liquids, ability to 
prepare meals/do household tasks, ability to perform daily functions, ability to perform usual 
recreation/leisure activities, willingness to spend time with family and friends, extent to which the 
side effect has caused personal hardship and hardship on others. 
Each item is answered using a 100-mm (1 to 7 points) VAS with anchors corresponding to 
“none/not at all” and “a great deal” and tick marks dividing the scale into six equal categories. The 
endpoint, no impact on quality of daily life is operationally defined as an average item score of >6 
on seven point scale. 
11.5
Time to Engraftment
Time to neutrophil engraftment would be defined as an absolute neutrophil count (ANC) recovery 
to ≥ 500 cells/mm3 sustained for 48 hours of ANC ≥ 1000 cells/mm3 sustained for 24 hours. Day 
one of neutropenia would be the first day post conditioning chemotherapy where the ANC < 1000 
cells/mm3.
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
Time to platelet engraftment would be defined as a platelet count recovery ≥ 100,000/µL 
sustained for 48 hours. Day one of thrombocytopenia would be the first day post conditioning 
chemotherapy where the ANC < 100,000/µL.
12. CRITERIA FOR REMOVAL FROM STUDY
Patients may be removed from the study at any point deemed appropriate by the Principal 
Investigators, Co-Investigators, or if requested by the patient. However, once the pre-transplant 
conditioning regimen is given, patients will continue on study until after administration of anti-emetic 
regimen and will receive supportive care as appropriate. Failure to use preventative anti-emetic 
medications after conditioning chemotherapy would most likely result in significant nausea and 
vomiting.
13. BIOSTATISTICS
The population under study is adult patients with high risk or advanced malignancies requiring an 
autologous stem cell transplantation with melphalan as part of the conditioning regimen. Based on the 
literature, a 60% CR in the control group was calculated by the weighted average of three aprepitant 
studies and 70% CR in the treatment groups with a non-inferiority margin of 4%. An estimated sample 
size of is 429 patients (143 in each arm) was calculated based on the percent overall CR in both 
treatment groups in the Navari et al trial with 80% power. (Navari 2016). A pre-planned interim 
analysis will be performed after the inclusion of 210 patients. The accrual period will be approximately 
2-3 years.
The non-inferiority margin for this trial was estimated with the fixed margin method. Three placebo-
controlled trials were included in a meta-analysis to estimate the placebo effect size. We calculated 
the pooled risk difference with 95% CIs using a random-effects model. We considered the upper 
bound of the pooled CI to be M1 = -8%. We calculated M2 with 50% preserved-effect for RD and 
found our non-inferiority margin to be approximately 4%.  A sequential testing procedure will be used 
to test for both non-inferiority and superiority controlled at the 2.5% level. 
Each patient will be followed until discharge. 
14. RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES
14.1 Research Participant Registration
All patients will be provided written informed consent. Obtain informed consent by following 
procedures defined in section entitled Informed Consent Procedures. See Appendix 19.3 for Informed 
Consent.
Confirm eligibility as defined in the section entitled Criteria for Subject Eligibility (See Section 5). 
During the registration process registering subjects will be required to complete a protocol specific 
Eligibility Checklist (See Appendix 19.4). The Eligibility Checklist will be completed by the primary 
investigators or co-investigators  prior to admission and emailed to the Principal Investigators 
(heme_oncinpatientpharmacist@rush.edu). Once emailed, this will reserve the subject a spot in the 
study until confirmation of additional exclusion criteria on day of admission.
Confirmation of subject eligibility will be done by the oncology research pharmacist or SCT 
pharmacist on the day of admission. This is to account for documentation for the additional exclusion 
criteria that cannot be assessed prior to admission (Nausea and vomiting within 12 hours before 
planned high dose chemotherapy or any anti-emetic treatment within the last 24 hours; baseline 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
QTc). SCT pharmacists will confirm subject eligibility and document confirmation in a Research 
Admission Note in the subject’s chart (See Appendix 19.5). On the day of admission, if the subject 
does not meet the additional criteria as assessed by the pharmacist, the pharmacist is to contact the 
Principal Investigators to remove subjects from the study.
14.2 Randomization
Subjects who meet eligibility criteria on the day of admission will be included in randomization. A 
stratified randomization method will be used to control and balance age, gender, and conditioning 
chemotherapy regimens. A separate randomization block will be generated to account for age, 
gender and conditioning chemotherapy regimen. Subjects will be assigned to the appropriate blocks. 
The following blocks will be used for stratified randomization:

Block 1: One Day Melphalan; Age 18-65; Female

Block 2: One Day Melphalan; Age 18-65; Male

Block 3: One Day Melphalan; Age 66-80; Female

Block 4: One Day Melphalan; Age 66-80; Male

Block 5: Two Day Melphalan; Age 18-65; Female

Block 6: Two Day Melphalan; Age 18-65; Male

Block 7: Two Day Melphalan Age 66-80; Female

Block 8: Two Day Melphalan Age 66-80; Male

Block 9: BEAM Age 18-65; Female

Block 10: BEAM Age 18-65; Male

Block 11: BEAM Age 66-80; Female

Block 12: BEAM Age 66-80; Male
Randomization will be managed in an excel spreadsheet by the Principal Investigators. 
Randomization will occur once the Eligibility Checklist (Appendix 19.4) is completed and emailed by 
the primary investigators or co-investigators. Randomization results will be emailed to the recruiting 
attending physician and pharmacists. 
15. DATA MANAGEMENT ISSUES
The responsibilities of the investigators include project compliance, data collection, abstraction and 
entry, data reporting, regulatory monitoring, problem resolution and prioritization, and coordination of 
the activities of the protocol study team. 
The data collected for this study will be entered into a secure database. Source documentation will be 
available to support the computerized subject record.
15.1 Quality Assurance
Monthly registration reports will be generated to monitor subject accruals and completeness of 
registration data by the principal investigators. Routine data quality reports will be generated to 
assess missing data and inconsistencies by the principal investigators. Accrual rates and extent and 
accuracy of evaluations and follow-up will be monitored periodically throughout the study period and 
potential problems will be brought to the attention of the study team for discussion and action.
15.2 Data and Safety Monitoring
There are several different mechanisms by which clinical trials are monitored for data, safety, and 
quality. There are institutional processes in place for quality assurance and departmental procedures 
for quality control. During the protocol development and review process, each protocol will be 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
assessed for its level of risk and degree of monitoring required. Every type of protocol will be 
addressed, and the monitoring procedures will be established at the time of protocol activation.
16. PROTECTION OF HUMAN SUBJECTS
16.1 Privacy
RUMC may allow the use and disclosure of protected health information pursuant to a completed and 
signed Research Authorization for. The use and disclosure of protected health information will be 
limited to the individuals described in the Research Authorization form. A Research Authorization 
form must be completed by the Principal Investigator and approved by the IRB.
16.2 Serious Adverse Event (SAE) Reporting
Any SAE must be reported to the IRB as soon as possible but no later than 5 calendar days. The 
report should contain the following information:

Subject’s name

Medical record number

Disease/histology

Protocol number and title

Date the adverse event occurred

The adverse event

Relationship of the adverse event to the treatment

If the AE was expected

The severity of the AE

The intervention

Detailed text that includes the following:
o
An explanation of how the AE was handled
o
A description of the subject’s condition
o
Indication if the subject remains on the study
o
If an amendment will need to be made to the protocol and/or consent form.
16.3 Costs
The subject will be responsible for the costs of standard medical care, including the anti-emetic 
treatment, all hospitalizations, and any transplant related complications. 
17. INFORMED CONSENT PROCEDURES
Before protocol-specified procedures are carried out, consenting professionals will explain full details 
of the protocol and study procedures as well as the risks involved to participants prior to their 
inclusion in the study. Participants will also be informed that they are free to withdraw from the study 
at any time. All participants must sign an IRB approved consent form indicating their consent to 
participate. This consent form meets the requirements of the Code of Federal Regulations and the 
IRB of this Center. The consent form will include the following:

The nature and objectives, potential risks and benefits of the intended study

The length of study and the likely follow up required

Alternatives to the proposed study (This will include available standard and investigational 
therapies. In addition subjects will be offered an option of supportive care of therapeutic 
studies.)
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001

The name of the investigator(s) responsible for the protocol

The right of the participant to accept or refuse study interventions/interactions and to 
withdraw from participation at any time.
Before any protocol specific procedures can be carried out, the consenting professional will fully 
explain the aspects of subject privacy concerning research specific information. In addition to signing 
the IRB Informed Consent, all subjects must agree to the Research Authorization component of the 
informed consent form. Each participant and consenting professional will sign the consent form. The 
participant must receive a copy of the signed informed consent form.
18. REFERENCES
1.
Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology 
Clinical Practice Guidelines. J Clin Oncol. 29(31):4190-4198. 2011.
2.
Gralla RJ, Roila F, Tonato M, et al: MASCC/ESMO antiemetic guideline 2013. 
http://www.mascc.org/assets/Guidelines-Tools/mascc_guidlines_english_2014.pdf
3.
National Comprehensive Cancer Network. Anti-emesis v3.2018. Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed on September 18, 
2018  
4.
Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-
induced nausea and vomiting: a randomized phase III trial. J Support Oncol. Sep-Oct;9(5):188-
95. 2011.
5.
Alkeran® [package insert]. Research Triangle Park, NC. GlaxoSmithKline; 2008.
6.
Emend® [package insert]. Whitehouse Station, NJ. Merck & Co., Inc; 2006.
7.
Zyprexa® [package insert]. Indianapolis, IN. Eli Lilly and Company; 2013.
8.
Zofran®; Zofran ODT®; [package insert]. Research Triangle Park, NC. GlaxoSmithKline; 2013.
9.
Dexamethasone [package insert]. Columbus, OH. Roxane Laboratories, Inc. 2007.
10. Dexamethasone injection [package insert]. Deerfield, IL. Baxter Healthcare Corporation. 2004.
11. Stiff P, Fox-Geiman M, Kiley K, et al. Aprepitant vs. placebo plus oral ondansetron and 
dexamethasone for the prevention of nausea and vomiting associated with higly emetogenic 
preparative regimens prior to hematopoietic stem cell transplantation: A prospective, randomized 
double-blind phase III trial. Blood 114:2267, 2009 (abstr)
12. Giralt S, Mangan K, Maziarz R, et al. Three palonosetron regimens to prevent chemotherapy-
induced nausea and vomiting (CINV) in myeloma patients receiving multiple-day high-dose 
melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 22: 939-946. 2011
13. Slaby J, Trneny M, Prochazka B, et al. Antiemetic efficacy of three serotonin antagonists during 
high-dose chemotherapy and autologous stem cell transplant in malignant lymphoma. 
Neoplasma. 2000;27(5):319-22.
14. Ballen KK, Hesketh AM, Heyes C, et al. Prospective evaluation of antiemetic outcome following 
high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant. 2001 
Dec;28(11):1061-6. 
15. Einhorn LH, Grunberg SM, Rapoport B, et al. Antiemetic therapy for multiple-day chemotherapy 
and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell 
transplant: review and consensus statement. Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4.
16. Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor-antagonist aprepitant in high-dose 
chemotherapy (high dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, 
etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011 
Jun; 46(6):784-9. 
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
17. Pielichowski W, Barzal J, Gawronski K, et al. A triple-drug combination to prevent nausea and 
vomiting following BEAM chemotherapy before autologous stem cell transplantation. Transplant 
Proc. 2011 Oct;43(8):3107-10.
18. Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem 
cell transplant: results of a prospective, randomized trial  of aprepitant used with highly 
emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013. Jan;19(1):49-55.
19. Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. 
J Pain Symptom Manage. 2002; 23:546-550.
20. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by 
olanzapine. Eur J Pharmacol. 2001; 430:341-349.
21. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce 
patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic 
treatment. J Clin Oncol. 2006; 24:4472-4478.
22. Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for 
prevention of chemotherapy induced nausea and vomiting after high-dose melphalan in 
autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled 
phase III trial. J Clin Oncol. 2014; 32:1-8.
23. Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and 
vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) 
with 5-day recall. Support Care Cancer. 2033. 11:522-527.
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
19. APPENDIX
19.1
Subject Diary
The following is to be completed on Day 0 to Day + 6 every morning. This is an example of Day 0.
Patient Diary 
Day 0 (0-24 hours)
Patient Name:
Date:
Patient signature:
Witness initials:
I.
Vomiting Assessment
1. Have you experienced any vomiting in the past 24 hours?                         
a. If YES, how many episodes?  ________________________
2. Have you experienced any retching or dry heaving in the past 24 hours?  
3. Have you used any rescue medication to treat your nausea or vomiting
In the past 24 hours?                                       
Y1  N0
Y1  N0
Y1  N0
II.
Nausea Assessment
4. In the past 24 hours, how has your nausea been? Please circle number below.
No 
nausea
0
1
2
3
4
5
6
7
8
9
10
Nausea as 
bad as it 
could be
III.
Mucositis Assessment
5. In the past 24 hours, how has your mouth pain been? Please circle number below.
No 
mouth 
pain
0
1
2
3
4
5
6
7
8
9
10
Mouth 
pain as 
bad as it 
could be
V. 
Notes  
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
19.2
FLIE Questionnaire
The following is to be completed at baseline, on Day -1 (if Day -1 is different than baseline) and 
repeated the morning of Day +5.
Patient FLIE Questionnaire 
Day + 5
Patient Name:
Date:
Patient signature:
Witness initials:
I.
Nausea
1. How much nausea have you experienced in the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
2. Has nausea affected your ability to maintain usual recreation or leisure activities 
during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
3. Has nausea affected your ability to make meals or do tasks during the past 5 
days?
A great deal
1
2
3
4
5
6
7
Not at all
4. Has nausea affected your ability to enjoy meals during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
5. Has nausea affected your ability to enjoy fluids during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
6. Has nausea affected your ability to see family/friends during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
7. Has nausea affected your daily functioning during the past 5 days?
A great deal
Not at all
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
1
2
3
4
5
6
7
8. Has nausea affected your personal hardship during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
9. Has nausea affected your hardship on others during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
II.
Vomiting
1. How much vomiting have you experienced in the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
2. Has vomiting affected your ability to maintain usual recreation or leisure activities 
during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
3. Has vomiting affected your ability to make meals or do tasks during the past 5 
days?
A great deal
1
2
3
4
5
6
7
Not at all
4. Has vomiting affected your ability to enjoy meals during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
5. Has vomiting affected your ability to enjoy fluids during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
6. Has vomiting affected your ability to see family/friends during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
7. Has vomiting affected your daily functioning during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
8. Has vomiting affected your personal hardship during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
9. Has vomiting affected your hardship on others during the past 5 days?
A great deal
1
2
3
4
5
6
7
Not at all
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
19.3
Informed Consent
Subject Information and Consent Form
See separate document
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
19.4
Eligibility Checklist
To be filled out by the primary investigators or co-investigators prior to admission and emailed to the 
Principal Investigators. All pertinent demographics (age and gender) and medical data (site, 
underlying malignancy, ECOG rating, and conditioning chemotherapy) will be recorded. Once 
emailed, this will reserve the subject a spot in the study until confirmation of additional exclusion 
criteria on day of admission.
I.
Patient Demographics
Name:
Age (years):
Gender:  Choose an item.
II.
Medical Data
Practice Site: Choose an item.
Underlying Malignancy: Choose an item.
ECOG: Choose an item.
Conditioning Chemotherapy: Choose an item.
III. 
Eligibility Assessment 
Inclusion
1. The patient is between 18-80 years of age
2. The patient is receiving an auto SCT with melphalan or BEAM
3. The patient can tolerate oral medications
Exclusion
4. The patient does not have a history of seizures
5. The patient is not pregnant
6. The patient does not have HIV
7. The patient does not have previous history of CNS disease
I attest that the patient meets the above criteria.
Recruiting attending physician: Choose an item.
Date: Click here to 
enter a date.
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


RUSH UNIVERSITY MEDICAL CENTER
IRB PROTOCOL
IRB#:  14102001
19.5
Research Admission Note
The Research Admission Note is to be completed by a SCT or research pharmacist the day the 
subject is admitted. This is to account for additional exclusion criteria that cannot be assessed prior to 
admission (Nausea and vomiting within 12 hours before planned high dose chemotherapy or any anti-
emetic treatment within the last 24 hours; QTc) and to provide a calendar for treatment schedule. 
SCT pharmacists will confirm subject eligibility and document confirmation using this Research 
Admission Note. On the day of admission, if the subject does not meet the additional criteria as 
assessed by the pharmacist, the pharmacist is to contact the Principal Investigators to remove 
subjects from the study.
Research Admission Note
This is a research note for IRB#14102001. The purpose of this note is to confirm patient 
eligibility and to document treatment randomization.
I have confirmed patient has not experienced any nausea or vomiting within 12 hours or 
any anti-emetic treatment within 24 hours before planned high dose chemotherapy. I 
have also confirmed that patient baseline QTc < 500 ms by checking the results of the 
required pre-admission EKG.
Patient has been randomized to ARM (A/B/C). 
Calendar of patient diary and questionnaires:
Day
Date
Patient form to be completed
Baseline
FLIE Questionnaire
-1
FLIE Questionnaire (if Day -1 is different 
from baseline date)
0
Patient Diary
+1
Patient Diary
+2
Patient Diary
+3
Patient Diary
+4
Patient Diary
+5
Patient Diary AND FLIE Questionnaire
+6
Patient Diary
ORA: 14102001-IRB01   Date IRB Approved: 10/1/2018   Amendment Date: 4/22/2019


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 1 of 8
CONSENT/AUTHORIZATION FOR PARTICIPATION IN A RESEARCH 
STUDY
Site Principal Investigator:
Amanda Seddon, PharmD
Department:
Inpatient Pharmacy
Address and Contact Information: Rush University Medical Center, 1653 W Congress 
Parkway, 312-947-2406
Protocol Title:
Aprepitant- and olanzapine- containing regimens for 
prevention of acute and delayed nausea and vomiting 
associated with high dose melphalan and BEAM in 
autologous stem cell transplant patients
Sponsor(s):
Rush University Medical Center
Name of Participant:  __________________________________________________________
Key Information:
You are being invited to participate in a research study. Research studies answer important 
questions that might help change or improve the way we do things in the future.
This consent form will give you information about the study to help you decide whether you 
want to participate. Please read this form, and ask any questions you have, before agreeing to be 
in the study.
Taking part in this research study is voluntary. You do not have to participate in this study and 
may choose to leave the study at any time. If you decide not to participate in this study or leave 
the study at a later time, your health care, benefits, or relationship with Rush University Medical 
Center will not change or be affected.
The purpose of this study is to determine whether administration of an aprepitant-containing 
regimen, an olanzapine-containing regimen, or an aprepitant plus olanzapine containing regimen 
will prevent nausea and vomiting better for patients undergoing an autologous stem cell 
transplant with melphalan chemotherapy. Both of these medications are approved by the United 
States Food and Drug Administration (FDA) for nausea and vomiting.
If you agree to participate in this study, your participation may last up to 7 days after you have 
completed chemotherapy. The expected minimal study duration would be approximately 7-14 
days, all during your hospitalization for your transplant. No additional visits are needed.
During your hospitalization, you will be asked to complete surveys about your nausea and how it 
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 2 of 8
is impacting your comfort level. For a detailed list of study procedures, please see the “What are 
the activities you will be doing if you participate in this study?” section of this consent form.
There are risks to you for participating in this study. In this study, there are risks of side effects 
with the medications included or you may become uncomfortable answering some of the 
questions. However, with any medication, side effects are possible. 
Very common side effects of aprepitant include fatigue (feeling tired), constipation, diarrhea, 
hiccups, nausea, hair loss, and anorexia (loss of appetite). Rare but serious side effects include 
Stevens-Johnson syndrome/toxic epidermal necrolysis (serious skin reaction, potentially life-
threatening) and allergic reactions.
Very common side effects of olanzapine include dizziness, postural hypotension (low blood 
pressure), constipation, somnolence (sleepiness), and tremor (shaking). Other likely side effects 
include hyperglycemia (high blood sugar), hyperlipidemia (high blood lipids), weight gain, and 
increased appetite. Rare but serious side effects include seizures, tardive dyskinesia 
(uncontrolled movement of body parts), neuroleptic malignant syndrome (life-threatening 
condition, symptoms include fever, sweating, muscle stiffness, confusion, unstable blood 
pressure etc.), and neutropenia (very low white blood count, which may increase your risk of 
infection). Boxed warnings for increased risk of death and suicide are reported for patients who 
are elderly with dementia-related psychosis (a severe mental disorder) who are prescribed 
olanzapine for treatment.
 For a detailed list of risks you should know about, please see the “What are the risks and 
discomforts of participating in this study?” section of this consent form.
You may benefit from taking part in this study. Based on experience with anti-emetic regimens 
in patients with similar conditions, researchers believe it may be of benefit to people receiving 
similar chemotherapy or it may be as good as standard therapy with fewer side effects. However, 
because individuals respond differently to therapy, no one can know in advance if it will be 
helpful for you.
There are other options available to you if you decide not to participate in this study. You may 
choose another regimen for prevention of nausea and vomiting with chemotherapy without being 
in a study such as:

A regimen not containing either aprepitant or olanzapine

A regimen containing aprepitant while electing not to participate in the study

A regimen containing olanzapine while electing not to participate in the study

A regimen containing olanzapine plus aprepitant while electing not to participate in the study
 
Detailed Information: Please review the rest of this document for details about 
the above topics and additional information you should know before making a 
decision about whether or not you will participate in this study.
Why are you being invited to participate in this study?
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 3 of 8
You are being asked to take part in this study since you will be receiving an autologous stem cell 
transplant and will be receiving standard chemotherapy that is known to cause nausea and 
vomiting.
How many participants will take part in this study?
About 429 study subjects will be taking part in this study, and approximately 75 are expected to 
be from Rush.
What are the activities you will be doing if you participate in this study?
If you agree to be in this study, it is important that you are completely honest with the doctor and 
staff about your health history. Before enrollment, your doctor will determine if you would be a 
candidate for this study. Besides your past medical history, you will need to obtain an 
electrocardiogram (ECG) to check the electrical activity of your heart. This is routinely done 
before any autologous stem cell transplant.
Prior to starting and once you begin chemotherapy you will be asked to fill out a patient diary. 
This diary contains 5 questions to be answered every day for 7 days. These questions will help us 
asses your nausea, vomiting, and mouth pain. In addition, you will be asked to fill out a 
questionnaire on quality of life on 2-3 days during the study. 
You will be asked to take a specified regimen of medications to prevent nausea and vomiting 
while hospitalized. No additional visits after your discharge from the hospital are required. No 
additional procedures will be needed. No additional blood tests are needed.
What are the risks and discomforts of participating in this study?
Side effects, risks, and/or discomforts from participation in this study may include side effects 
from the anti-nausea medications utilized.
Very common side effects of aprepitant include fatigue (feeling tired), constipation, diarrhea, 
hiccups, nausea, hair loss, and anorexia (loss of appetite). Rare but serious side effects include 
Stevens-Johnson syndrome/toxic epidermal necrolysis (serious skin reaction, potentially life-
threatening) and allergic reactions.
Very common side effects of olanzapine include dizziness, postural hypotension (low blood 
pressure), constipation, somnolence (sleepiness), and tremor (shaking). Other likely side effects 
include hyperglycemia (high blood sugar), hyperlipidemia (high blood lipids), weight gain, and 
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 4 of 8
increased appetite. Rare but serious side effects include seizures, tardive dyskinesia 
(uncontrolled movement of body parts), neuroleptic malignant syndrome (life-threatening 
condition, symptoms include fever, sweating, muscle stiffness, confusion, unstable blood 
pressure etc.), and neutropenia (very low white blood count, which may increase your risk of 
infection). Boxed warnings for increased risk of death and suicide are reported for patients who 
are elderly with dementia-related psychosis (a severe mental disorder) who are prescribed 
olanzapine for treatment.
We are studying the addition of aprepitant and olanzapine to these combination regimens 
currently used. The additional medications used in the combinations are listed below.
Ondansetron
Side effects include headache, malaise (feeling sick), fatigue (tiredness), constipation, diarrhea, 
and dizziness. Rare but serious side effects reported include serious allergic reactions, and heart 
rhythm disorder (QT interval prolongation).
Dexamethasone or other corticosteroids
The side effects reported by patients taking dexamethasone include edema (fluid retention), high 
blood pressure, sodium retention and/or potassium loss, increased appetite and weight gain, 
extreme mood swings, tiredness, depression, inability to sleep, nausea, vomiting. Patients may 
also experience increased sweating, increased blood sugar, irregularities in the menstrual cycle, 
excess hair, thinning of bone, increased risk of picking up infections or mild infections get 
worse, hiccups, abdominal pain, stomach ulcers, and skin disorders. Additionally, some patients 
reported allergic reactions, blood clots, eye disorders including increased eye pressure. Patients 
with pre-existing schizophrenia (a severe mental disorder), epilepsy (seizures) may experience 
worsening of their disease; patients with heart disease may experience heart failure. The longer a 
patient takes these drugs and the larger the dose may increase the incidence of the side effects 
listed above. 
There may be other risks that may happen that we cannot predict.
What are the reproductive risks of participating in this study?
You will be screened for pregnancy prior to enrollment in this study as part of the routine work 
up for autologous stem cell transplant. Patients who are pregnant are not eligible for autologous 
stem cell transplant and therefore not eligible for this study.
What if there is new information that may affect your decision to participate in this study?
During this study, you will be told about important findings (either good or bad), such as changes 
in the risks or benefits of participation in the study or new choices to participation that might 
cause you to change your mind about being in the study. If new information is shared with you, 
you may be asked to sign a revised consent form in order to continue participating in this study.
Can you leave or be removed from this study?
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 5 of 8
You have the right to leave a study at any time without penalty. You are free to withdraw from 
this study at any time you choose without giving a reason.  This will not affect any future care 
you will receive.  
The researchers and sponsor also have the right to stop your participation in this study without 
your consent if:

They believe it is in your best interests;

You do not follow the instructions;

The study is cancelled for any reason.
What about confidentiality of your medical information?
This authorization is voluntary. Rush University Medical Center and its affiliates (“Rush”) will 
not withhold or refuse your treatment, payment, enrollment, or eligibility for benefits if you sign 
this authorization. You do not have to sign this authorization, but that means that you cannot be 
in the study or receive study-related treatment.
By signing this document, you voluntarily authorize (give permission to) Dr. Amanda Seddon, 
her study team, and other Rush personnel involved with the conduct and review of this study 
(which may include off-site personnel) to use or disclose (release) health information that 
identifies you for the study described in this document.
During the study, Dr. Amanda Seddon and her study team will collect Protected Health 
Information (PHI) about you for the purposes of this research. PHI is your health information 
that includes your medical history and new information obtained as a result of this study. Some 
of this information will come from your medical record. The health information that Rush may 
use or disclose for this research includes:

All information in a medical record with specific focus on use of nausea and vomiting 
medications, physical examination results specifically for mucositis or nausea and 
vomiting, completed patient diaries
Dr. Amanda Seddon and her study team may share your health information and the results of 
your study-related procedures and tests with people outside of Rush who assist with the conduct 
and review of this study. The persons who receive your health information may not be required 
by Federal privacy laws to protect it and may share your information with others without your 
permission, but only if permitted by the laws governing them. Your health information described 
above may be used or disclosed to:

To the Researchers 

Monitoring agencies such as the Food and Drug Administration (FDA), the National 
Institutes of Health and the Rush Institutional Review Board (IRB).
While you participate in the study you will have access to your medical record, but Dr. Amanda 
Seddon is not required to release to your study information that is not part of your medical 
record. Rush is required by law to protect your health information, and study records that 
identify you will be kept confidential. The results of study tests/procedures performed as part of 
this study may become part of your medical record. Any study information in your medical 
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 6 of 8
record will be kept indefinitely. Your identity will not be revealed on any report, publication, or 
at scientific meetings. 
You have a right to inspect and copy the information to be disclosed with this authorization and 
you may obtain a copy of the information by contacting the office listed above.
If you no longer want to be in the study and do not want your future health information to be 
used, you may change your mind and revoke (take back) this authorization at any time by writing 
to Dr. Amanda Seddon at 1653 W Congress Parkway, Chicago, IL 60612. If the authorization is 
revoked, you will no longer be allowed to participate in the study and previously authorized 
individuals/entities may still use or disclose health information that they have already obtained 
about you as necessary to maintain the integrity or reliability of the current study.
This authorization is valid for the entirety of this research study. It will expire upon your 
completion of the study or if you revoke (take back) the authorization.
If you withdraw from this study, the data already collected from you may not be removed from 
the study records. The study doctor and/or study team may ask you whether they can continue to 
collect follow-up data on you. If follow-up information will be requested, you will be asked to 
sign a separate consent form before this information can be collected.
Records of participation in this study will be maintained and kept confidential as required by 
law. Participants will be assigned an identification number and identifying information will be 
removed.
The Rush Institutional Review Board (IRB) will have access to your files as they pertain to this 
research study. The IRB is a special committee that reviews new and ongoing human research 
studies to check that the rules and regulations are followed regarding the protection of the rights 
and welfare of human participants.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time. This 
research study can be found by searching for the following Clinical Trial Registry Number 
(NCT#): NCT02939287.
What are the costs to participate in this study?
There are no costs to you for participating in this research.
Will you be paid for your participation in this study?
You will not be paid for being in this study.
What if you are injured as a result of your participation in this study? 
If you get ill or injured from being in the study, Rush University Medical Center will help you 
get medical treatment. You should let the study doctor know right away that you are ill or 
injured. If you believe you have become ill or injured from this study, you should contact Dr. 
Amanda Seddon at telephone number 312-947-2406.
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 7 of 8
You should let any health care provider who treats you know that you are in this study. If you do 
seek medical treatment, please take a copy of this document with you because it may help the 
doctors where you seek treatment to treat you. It will also provide the doctors where you seek 
treatment with information they may need if they want to contact your study doctor.
You or your health insurance plan will be billed. No money has been set aside to pay the costs of 
this treatment. Health insurance plans may or may not cover costs of research-related injury or 
illness. You should check with your insurance company before deciding to participate in this 
research study. 
Rush University Medical Center has no program for financial compensation or other forms of 
compensation for injuries which you may incur as a result of participation in this study.
By signing this form, you are not giving up any legal rights to seek compensation of injury.
What other information should you know about?
Your transplant team, who are the persons responsible for this research study, are interested in 
both your clinical care and the conduct of this study. You have the right to discuss this study 
with another person who is not part of the research team before making your decision whether or 
not to be in the study.
Who can you contact for more information about this study?
Questions are encouraged. If you have further questions about this study, you may call Amanda 
Seddon, PharmD at 312-947-2406 or email her at Amanda_N_Seddon@rush.edu. 
Who can you contact if you have concerns about your rights as a study participant?
Questions about the rights of research participants may be addressed to the Rush University 
Medical Center Office of Research Affairs at 1-800-876-0772.
What are your rights as a study participant?
Taking part in this study is voluntary. If you choose not to participate in this study or to leave the 
study at any time, your health care, benefits or relationship at Rush University Medical Center 
will not change or be affected.
If you choose to leave this study and you do not want any of your information to be used, you 
must inform Dr. Seddon in writing at the address on the first page. Dr. Seddon may still use your 
information that was collected prior to your written notice.
SIGNATURE BY THE PARTICIPANT:
By signing below, you are consenting to participate in this research study. You have read the 
information given or someone has read it to you. You have had the opportunity to ask questions, 
which have been answered satisfactorily to you by the study staff. You do not waive any of your 
legal rights by signing this consent form. You will be given a signed copy of this consent.
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021


Rush Template Version Date: 12/10/2018
[Consent/Authorization Version Date: 04/20/2019]
Page 8 of 8
_________________________________
_______________________ __________________
Name of Participant
Signature of Participant
Date of Signature
SIGNATURE BY THE INVESTIGATOR/INDIVIDUAL OBTAINING CONSENT:
I attest that all the elements of informed consent described in this consent document have been 
discussed fully in non-technical terms with the participant. I further attest that all questions asked 
by the participant were answered to the best of my knowledge.
_______________________________________________________
__________________
Signature of Individual Obtaining Consent
Date of Signature
ORA: 14102001-IRB01   Date IRB Approved: 2/26/2021   Expiration Date: 2/26/2022   Amendment Date: 11/22/2021